The Market LogEnter at least 2 characters. Company and ticker searches are not case-sensitive.

Transaction #8395 · Form 4 · 0001380762-25-000005

ARS Pharmaceuticals, Inc. · Exercise / conversion · Common Stock

ARS Pharmaceuticals, Inc. · Transacted November 13, 2025 · Filed November 14, 2025

Original SEC filing ↗

What does this filing report?

An SEC Form 4 filing for ARS Pharmaceuticals, Inc. records an exercise / conversion involving Common Stock on November 13, 2025. The reported quantity was 21,828. The filing date is November 14, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Transaction details

Company CIK
0001671858
Security type
Non-derivative
Acquisition type
Exercise / conversion · Code M
Quantity acquired
21,828
Reported price
0.64
Reference value
13,969.92
Currency
Currency not specified
Ownership
Direct
Holdings after transaction
32,617
Ownership description
Not reported
SEC acceptance time
Nov 14, 2025, 6:43 PM EST
10b5-1 indication
Not indicated

Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.

Reporting owners

These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.

Company listings

SPRY · Nasdaq · linked security

The linked listing is identified separately from other current company listings.

Filing footnotes & remarks

F1
Includes 1,628 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on December 31, 2024 and 3,137 shares acquired under the ESPP on June 30, 2025.
F2
The weighted average sale price for the transaction report was $8.7067, and the range of prices was between $8.63 and $8.835. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3
Immediately exercisable.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.

This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.